Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys
2023; Elsevier BV; Volume: 87; Issue: 6 Linguagem: Inglês
10.1016/j.jinf.2023.10.008
ISSN1532-2742
AutoresCraig Fenwick, Priscilla Turelli, Yoan Duhoo, Kelvin Lau, Cécile Hérate, Romain Marlin, Myriam Lamrayah, Jérémy Campos, Line Esteves-Leuenberger, Alex Farina, Charlène Raclot, Vanessa Genet, Flurin Fiscalini, Julien Cesborn, Laurent Perez, Nathalie Dereuddre‐Bosquet, Vanessa Contreras, Kyllian Lheureux, Francis Relouzat, Rana Abdelnabi, Pieter Leyssen, Yves Lévy, Florence Pojer, Roger Le Grand, Didier Trono, Giuseppe Pantaleo,
Tópico(s)COVID-19 Clinical Research Studies
ResumoDue to the rapid evolution of SARS-CoV-2 to variants with reduced sensitivity to vaccine-induced humoral immunity and the near complete loss of protective efficacy of licensed therapeutic monoclonal antibodies, we isolated a potent, broad-spectrum neutralizing antibody that could potentially provide prophylactic protection to immunocompromised patient populations.
Referência(s)